We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial Comparing 19 and 25-gauge EUS-FNA Needles (EUS-FNA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01677312
First Posted: September 3, 2012
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Alabama at Birmingham
Information provided by (Responsible Party):
Florida Hospital
  Purpose
This study compares the 19G and 25G needles for procuring tissue samples from the pancreas during Endoscopic Ultrasound (EUS) procedures.

Condition Intervention
Solid Pancreatic Mass Lesions Procedure: Pancreatic Biopsy Procedure: Histological Samples

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Multi-Center Randomized Trial Comparing 19 and 25-gauge Needles for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) of Solid Pancreatic Mass Lesions

Further study details as provided by Florida Hospital:

Primary Outcome Measures:
  • Median number of passes to establish diagnosis [ Time Frame: 12 months ]
    To compare the median number of passes required to establish diagnosis using the 19G and 25G needles for FNA of solid pancreatic mass lesions. This will be measured by comparing the rates of diagnostic accuracy (%) between both needle types.


Secondary Outcome Measures:
  • Procurement of histological samples [ Time Frame: 30 days ]
    The ability of the 19G and 25G needles to obtain core (histological) tissue will be compared as percentages (%) and a significance will be determined.

  • Needle dysfunction [ Time Frame: 2 hours ]
    The proportion of cases (%) in which needle dysfunction occurs will be compared between the 19G and 25G needle types. Needle dysfunction will be defined as the need to use more than one FNA needle per lesion in an individual patient.

  • Complications [ Time Frame: 30 days ]
    The safety profile of the 19 and 25G needles will be compared as rates of complication (%) that includes bleeding, pancreatitis and perforation.


Enrollment: 109
Study Start Date: August 2012
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 19G FNA needle
Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 19G FNA needle when performing pancreatic biopsy.
Procedure: Pancreatic Biopsy
A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
Procedure: Histological Samples
The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
Active Comparator: 25G FNA needle
Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 25G FNA needle when performing pancreatic biopsy.
Procedure: Pancreatic Biopsy
A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
Procedure: Histological Samples
The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.

Detailed Description:
The study compares the median number of passes to establish a definitive diagnosis using the 19G or 25G needles. Also, the ability of both needles to procure a histological core tissue is assessed.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

(1) Patients with solid pancreatic mass lesions.

EXCLUSION CRITERIA:

  1. Age < 19 years
  2. Unable to safely undergo EUS for any reason
  3. Coagulopathy (INR > 1.6, Prothrombin Time > 18secs, Thrombocytopenia < 80,000 cells/ml)
  4. Unable to consent
  5. Non-English speaking patients
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01677312


Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, Florida
Florida Hospital
Orlando, Florida, United States, 32814
Sponsors and Collaborators
Florida Hospital
University of Alabama at Birmingham
Investigators
Principal Investigator: shyam varadarajulu, MD Florida Hospital Center for Interventional Endoscopy
  More Information

Responsible Party: Florida Hospital
ClinicalTrials.gov Identifier: NCT01677312     History of Changes
Other Study ID Numbers: 356077
First Submitted: August 28, 2012
First Posted: September 3, 2012
Last Update Posted: October 12, 2017
Last Verified: March 2013